Clinical Trials in Ukraine from 2027: What Will Change for Sponsors, CROs and Research Sites
Contents
- New rules from 2027: regulatory model and transition
- How expert evaluation timelines are changing
- Electronic submission of documents and applicant authorisations
- Roles of the sponsor, CRO and research site
- Informed consent, ethical review and medical data
- Contracts, payments and liability of the parties
- Inspection of clinical trials from 2027
- What should be checked before the first submission in 2027
- How GOLAW can help prepare for the 2027 rules
The Ukrainian clinical trials market is recovering. According to the data of the State Expert Center of the Ministry of Health of Ukraine (the “SEC”), in 2025, following expert evaluations, 81 clinical trials were recommended for conduct in Ukraine, and 76 studies were launched. The number of studies launched in 2025 increased by 24.6% compared with 2024. This confirms Ukraine’s gradual return to more active participation in international clinical research programmes.
At the same time, the market is entering a significant regulatory update. Under the version in force as at the date of publication, from 1 January 2027, a new procedure for conducting clinical trials of medicinal products, approved by MoH Order No. 184, is expected to start applying. The Order comes into force simultaneously with the introduction into effect of the Law of Ukraine “On Medicinal Products” No. 2469-IX; the main body of the Law’s provisions is introduced into effect from 1 January 2027, while certain provisions are introduced into effect from 1 January 2028.
For sponsors, contract research organisations (the “CROs”), research sites, clinics and laboratories, this is not a formal replacement of one order by another. Decisions made before the submission of documents – who acts as the applicant, which functions are delegated to the CRO, how contracts with sites are structured, how authorisations, informed consent, data processing and payments are arranged – will directly affect the timelines for launching a study and inspection readiness. Therefore, preparation for the 2027 rules should reasonably begin before the first submission, rather than after receiving comments from the regulator.
New rules from 2027: regulatory model and transition
At present, the procedure for conducting clinical trials of medicinal products is determined by MoH Order No. 690. Under the current regulatory model, from 1 January 2027 it is expected to be replaced by the procedure approved by MoH Order No. 184.
The new procedure generally preserves the scope of regulation: it covers clinical studies/trials of medicinal products, including advanced therapy medicinal products, but does not apply to non-interventional studies. The practically important changes concern the procedural model, expert evaluation timelines, the powers of the state control authority, ethical review, informed consent, electronic submission of documents and inspection.
The institutional transition should be considered separately. On 4 June 2026, the Cabinet of Ministers of Ukraine, by Resolution No. 739, established the Ukrainian Pharmaceutical Agency as a central executive authority with special status. The Regulation on the Ukrainian Pharmaceutical Agency directly assigns to it the powers of expert evaluation of clinical trial materials, adoption of decisions on their conduct and inspection. The MoH states that the legal preconditions have been created for the Agency to start operating from 1 January 2027.
At the same time, the transitional mechanisms require careful distinction. In January 2026, the MoH reported that during 2027 the SEC would complete the expert evaluation of materials submitted by 31 December 2026 to ensure the continuity of procedures for the state registration of medicinal products. This wording should not be automatically extended to clinical trial materials. As at August 2026, the MoH also noted that the legal and practical issues of the transition to the new model were still being worked through.
For sponsors and CROs planning submissions at the end of 2026 or the beginning of 2027, this creates a separate practical risk. It is advisable to determine the submission strategy in advance, check who will act as the applicant, who will have the right to submit documents and conduct regulatory communication, and whether the authorisations and contracts between the sponsor, the CRO, the research sites and other involved parties are aligned.
How expert evaluation timelines are changing
Orders No. 690 and No. 184 determine timelines according to different logic. The current procedure establishes a general expert evaluation timeline and special rules for certain categories. The new procedure links the timeline primarily to the type of clinical trial and its characteristics.
Under Order No. 690, the general timeline for the SEC’s expert evaluation is no more than 30 calendar days. For a clinical trial involving the use of an investigational advanced therapy medicinal product, the timeline is 79 calendar days; the SEC may extend it by another 50 calendar days for consultations with specialists. After receiving the SEC’s conclusion, the current procedure separately provides up to 5 calendar days for the MoH to adopt a decision.
Under Order No. 184, expert evaluation begins from the date of submission of the complete document package and lasts:
- no more than 50 calendar days for interventional clinical trials;
- no more than 20 calendar days for low-intervention clinical trials; and
- no more than 25 calendar days for international multicentre Phase II–III clinical trials whose protocols have been agreed or approved in countries with stringent regulatory authorities or through the centralised procedure by the competent authority of the European Union.
Accordingly, for launch planning, not only the number of days itself matters, but also the correct qualification of the study and confirmation of the criteria on which the applicable timeline depends. International sponsors and CROs should factor this into the overall launch schedule, budgeting, arrangements with research sites and communication with the global team.
At the same time, the statutory timeline is not the same as the actual launch timeline. An incomplete document package, improperly executed applicant authorisations, documents not aligned between the parties, or delays in responding to comments may neutralise the advantage of an accelerated procedure. This is why legal review of the package should reasonably be conducted before submission.
Electronic submission of documents and applicant authorisations
The electronic format is already used in the current system. The SEC reported that from 1 April 2026, applications for clinical trials and substantial amendments, at the applicant’s discretion, may be submitted remotely through the Applicant’s Electronic Cabinet. MoH Order No. 184, in turn, provides for electronic submission of materials to the state control authority.
Electronic submission simplifies the communication channel, but not the requirements for the legal quality of documents. The applicant’s authorisations, proper execution of powers of attorney, the relevance of documents and clear identification of the persons entitled to submit materials and conduct correspondence remain critical.
For current electronic submissions, the SEC expressly requires an authorisation/power of attorney from the sponsor if the applicant is not the sponsor, as well as a power of attorney or an official letter from the applicant regarding responsible employees. Under Order No. 184, if the applicant is not the sponsor, the package must include the sponsor’s power of attorney with clearly defined delegated powers.
The practical conclusion for a sponsor and a CRO is simple: the authorisation matrix must be ready by the start of the regulatory procedure. A discrepancy between the contract, the power of attorney and the actual allocation of functions may cause delays in submission, approval of substantial amendments and further interaction with the state control authority.
Roles of the sponsor, CRO and research site
The new procedure provides for interaction between the sponsor, applicant, CRO, healthcare institution, principal investigator/investigator, ethics committee, laboratories and other involved persons. At the same time, the key principle remains unchanged: the sponsor may delegate its functions in writing, but remains responsible for performance of the delegated function. Therefore, the contractual model and responsibility matrix should reflect the actual operational process.
The institution of a CRO itself is not new for Ukrainian regulation: the current Order No. 690 also provides for the possibility for the sponsor to delegate functions to a contract research organisation. Order No. 184 transfers this approach into the new regulatory model. In practice, this means that it is not enough for a contract with a CRO merely to name the list of services – it is necessary to clearly define which functions are delegated, who prepares and submits documents, who interacts with the state control authority and the ethics committee, who coordinates the sites and who retains evidence of the performance of the relevant actions.
If the contract, power of attorney, internal procedures and actual working model do not correspond to one another, the risk manifests itself not only in a dispute between the parties. It may lead to delays in approvals, payment issues, gaps in documentation and additional questions during inspection.
Informed consent, ethical review and medical data
MoH Order No. 184 approves not only the new procedure for conducting clinical trials, but also the requirements for the form and content of informed consent and the Model Regulations on the ethics committee of the healthcare institution where clinical trials are conducted.
Informed consent under the new procedure is defined as a voluntary decision of a person to participate in a specific clinical trial, documented in paper or electronic form, dated and signed by hand or with a qualified electronic signature after the person has been duly informed about the nature, significance, impact and risks of the study.
At the same time, electronic informed consent is not in itself a novelty of 2027: Order No. 690 already allows paper and electronic forms. The practical change lies in the inclusion of these requirements in the new regulatory model and in the separate approval of requirements for the form and content of informed consent.
Before launching a study, informed consent, documents concerning the processing of personal data, access to medical information, cross-border data transfers, the use of electronic systems, anonymisation or pseudonymisation of data and the actual flows of information between the site, the CRO and the sponsor should be checked separately. The new procedure does not replace separate requirements of personal data protection legislation and, where applicable, the GDPR.
For an international sponsor, it is particularly important that the Ukrainian document package does not contradict the global data processing model. A mismatch between informed consent, contracts, internal group rules and the actual transfer of data may delay the launch of a study or create a problem already during an inspection.
Contracts, payments and liability of the parties
MoH Order No. 184 directly provides for the conclusion of contracts between the sponsor or its authorised person, including a CRO, and a healthcare institution, and, in the cases provided for, a tripartite contract involving a higher education institution in the field of healthcare. Before the start of the study, a voluntary third-party liability insurance contract for the sponsor must also be concluded. It should also be taken into account that inspection may cover healthcare institutions, laboratories, the premises of the sponsor, CRO and other places connected with the study.
For CROs and research sites, it is critical that all contracts operate as a single system. If the contract with the sponsor provides for one scope of liability, while the contracts with sites, laboratories or other contractors provide for another, uncovered risks arise. Contract review should include payment terms and conditions, taxes, expense reimbursement, currency of payments, supporting documents, liability, insurance, force majeure, termination, inspection, confidentiality, intellectual property and engagement of contractors.
For Ukraine, currency regulation, bank checks and documentary confirmation of cross-border payments take on separate importance. Even a model that is correct from a regulatory perspective may create a delay if the contract, invoice, acceptance certificate, payment purpose and actual recipient of funds are not aligned with one another.
Therefore, the financial model of a clinical trial should be part of the legal structuring of the project, rather than an issue resolved after the contracts have been signed. This is particularly important for payment for the services of research sites, reimbursement of expenses, engagement of individuals and cross-border settlements.
Inspection of clinical trials from 2027
An official review mechanism already exists: Order No. 690 provides for clinical audit by the SEC. Under Order No. 184, the model changes to scheduled and unscheduled inspections by the state control authority. The subject matter of an inspection may include documents, records, premises, installations, equipment, quality assurance systems and other resources connected with the clinical trial.
Preparation for inspection should begin not after a notice of inspection is received, but at the study launch stage. Contracts, powers of attorney, correspondence, internal procedures, staff training, allocation of functions, informed consent, protocol versions, substantial amendments, protocol deviations and corrective and preventive actions should form a consistent documentary chain.
For the sponsor, CRO and research site, the greatest risk arises where the documents describe one process while the team actually works according to another. Such discrepancies should reasonably be identified during an internal readiness review, rather than during a regulatory inspection.
What should be checked before the first submission in 2027
The optimal approach is to conduct a legal readiness review not “in general” under the new legislation, but in relation to a specific study or portfolio of studies. The outcome should be a list of discrepancies, responsible persons and a plan for eliminating them before submission of documents.
For sponsors and CROs, the priorities are: the submission strategy at the turn of 2026/2027; the status and authorisations of the applicant; the delegated functions matrix; powers of attorney; contracts with sites and contractors; informed consent and data-related documents; tax and currency aspects of payments; and documentary readiness for inspection.
For research sites, private clinics and laboratories, the focus is different: contracts with the sponsor or CRO, delineation of team responsibilities, access to data, document retention, confirmation of staff training, work with informed consent and readiness to confirm the actual performance of procedures before the sponsor, the ethics committee or the state control authority.
How GOLAW can help prepare for the 2027 rules
For sponsors, CROs, research sites and other market participants, GOLAW can conduct a legal readiness review for the new regulatory model and prepare a practical action plan before the first submission. This work may cover the regulatory strategy, the structure of applicant authorisations, the delegation of functions matrix, contracts with sites and contractors, informed consent and documents concerning personal and medical data, payments, tax and currency matters and inspection readiness.
The GOLAW team can also support the implementation of the necessary changes: prepare or review contracts and powers of attorney, align local documents with the model of the international sponsor, structure payments, review the allocation of liability between the study participants and conduct a pre-inspection legal review of documentation. If submission is planned for the end of 2026 or the first quarter of 2027, such review should reasonably be conducted before the final document package is formed.
The article was written by:
Oleksandr Melnyk, Partner at GOLAW, Head of Corporate and M&A practice, Attorney at law
Vladyslava Zaichko, Junior Associate at Corporate and M&A practice at GOLAW
Oleksandr Melnyk
Partner, Head of Corporate Law and M&A practice, Attorney at law
- Contacts
- 31/33 Kniaziv Ostrozkykh St, Zorianyi Business Center, Kyiv, Ukraine, 01010
- o.melnyk@golaw.ua
- +38 044 581 1220
- Recognitions
- Lexology Index: Energy 2026
- Lexology Index: Client Choice 2026
- The Legal 500 2025
- IFLR1000 2025 (International Financial Law Review)
- Legal 500 Green Guide 2024
- 50 Leading Law Firms Ukraine 2026
Get in touch
To get a consultation, please fill out the form below or call us right away:Sign up to be aware
New achievements are inspired by information. GO further, don’t miss out GOLAW news and legal alerts
We use cookies to improve performance of our website and your user experience.
Cookies policy
Cookies settings